BioMarin's Initial 6-Month Data From Phase 2 Study of Vosoritide (BMN 111) in Children With Achondroplasia Presented at the American Society for Bone and Mineral Research Annual 2015 Meeting

BioMarin Pharmaceutical Inc. BMRN today announced that Dr. Melita Irving, Clinical Geneticist, Guy's and St Thomas' NHS Foundation Trust, Evelina Children's Hospital London, UK, presented the initial six-month data from the first three cohorts of a Phase 2 proof-of-concept and dose-finding study of vosoritide (BMN 111), an analog of C-type Natriuretic Peptide, in children with achondroplasia at the American Society for Bone and Mineral Research Annual 2015 Meeting in Seattle, Washington. Achondroplasia is the most common form of human dwarfism. The initial six-month data from the first three cohorts showed a 50 percent or 2.01 cm/year increase in mean annualized growth velocity (speed at which growth in children occurs) in the cohort of 10 patients receiving a 15 µg/kg dose of vosoritide daily for six months compared with their own pre-treatment growth velocity (p-value= 0.01). Data suggests that vosoritide activity was sustained over six months of dosing as measured by increases in cyclic guanosine monophosphate (cGMP), a urinary marker of pharmacological activity. No serious or severe adverse events were observed and the most common adverse events reported were mild injection site reactions, asymptomatic hypotension and headache that were resolved without medical intervention (Grade 1). BioMarin previously announced these data in June this year and indicated that these data would be presented at an upcoming medical meeting. "We are pleased to share this initial six-month data from the first three cohorts in a scientific forum, and we are grateful to the children, families and physicians who have participated in this study. By developing a therapy that addresses the root cause of achondroplasia, we hope to address the associated complications, such as disproportionate bone growth," said Hank Fuchs, M.D., Executive Vice President and Chief Medical Officer at BioMarin. "We are very encouraged with this initial data, and we look forward to working with health authorities and the patient community to advance vosoritide to the next stage of clinical development." While the Phase 2 efficacy endpoint centers on annualized growth velocity after six months of treatment, BioMarin believes that growth velocity may be an important early indicator and that longer treatment may lead to improvement in many of the complications that can be associated with achondroplasia, such as disproportionality, though longer time of treatment is likely required to accumulate evidence to this effect. Vosoritide is the designated generic name for BMN 111 and was issued by the International Nonproprietary Names (INN) system managed by the World Health Organization (WHO). Vosoritide has Orphan designation in both the United States and Europe. Phase 2 Study Design Children in this study completed or will have completed a minimum six-month natural history study to determine their respective baseline growth velocity prior to entering the Phase 2 study with vosoritide. The Phase 2 trial is an open-label, sequential cohort dose-escalation study of vosoritide in children with achondroplasia. In the current three dose cohorts, patients were treated with either 2.5 µg/kg, 7.5 µg/kg or 15 µg/kg/ daily, by subcutaneous injection. A total of 26 children with achondroplasia with an average age of 7.8 years were enrolled in the first three cohorts. Based on the safety profile observed to date across the three dose cohorts, all subjects participating in the study have now been switched to the dose of 15 µg/kg/ daily for the duration of the 18-month extension study. Additional cohorts for higher doses have been added to the study.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: NewsFDAPress Releases
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!